Results 291 to 300 of about 871,767 (407)

Comparing therapeutic effects across tyrosine kinase inhibitors: Chronic myeloid leukemia outcomes and analysis of influencing factors. [PDF]

Medicine (Baltimore)
Zhang Z, Jiang W, Ding S, Shen X.
europepmc   +1 more source

The specificities of small molecule inhibitors of the TGF beta and BMP pathways [PDF]

, 2011
Sapkota, Gopal P., Traynor, Ryan, Vogt, Janis   +2 more
core   +2 more sources

254 Tyrosine kinase inhibitors

European Journal of Cancer Supplements, 2009
openaire   +2 more sources

Mitochondrial Regulation of CD8⁺ T Cells: Mechanisms and Therapeutic Modulation

Advanced Science, EarlyView.
This article comprehensively explores the pivotal role of mitochondrial function in CD8⁺ T cell immunotherapy. It highlights how mitochondrial dynamics regulate T cell activation, differentiation, and persistence, and how mitochondrial dysfunction leads to immune exhaustion and impaired antitumor/antiviral responses.
Xu Chen, Pei Lin, Ye Lu, Jiarong Zheng, Yunfan Lin, Zihao Zhou, Li Cui, Xinyuan Zhao   +7 more
wiley   +1 more source

Target prices for mass production of tyrosine kinase inhibitors for global cancer treatment [PDF]

, 2015
Bower, M, Erbacher, I, Fortunak, J, Gotham, D, Hill, A, Levi, J, Martin, M, Meldrum, J, Powderly, WG, Shoman, HASA   +9 more
core   +1 more source

Drug Delivery Technologies for the Treatment of Age‐Related Macular Degeneration

Advanced Science, EarlyView.
There are multiple therapeutic agents available for the treatment of both dry age‐related macular degeneration (AMD) and wet AMD. It is essential to continue innovation by introducing new drug delivery technologies that can incorporate those along with patient compliance and the accessibility of the technology into the early stages of research and ...
J Jesus Rodriguez‐Cruz, Jessica Cutrufello, Michael Lam, Shreya Nallaparaju, Nicholas A. Peppas   +4 more
wiley   +1 more source

Covalent Bruton tyrosine kinase inhibitors across generations: A focus on zanubrutinib. [PDF]

J Cell Mol Med
Broccoli A, Del Re M, Danesi R, Zinzani PL.   +3 more
europepmc   +1 more source

Splicing Shift of RAC1 Accelerates Tumorigenesis and Defines a Potent Therapeutic Target in Lung Cancer

Advanced Science, EarlyView.
Dysregulated RNA splicing is an underappreciated molecular feature of cancer. By integrating murine and cellular models with patient specimens of lung adenocarcinoma, this study demonstrates that RAC1B, rather than RAC1A isoform, promotes tumorigenesis and presents a potent therapeutic target for lung cancer. Mechanistically, RAC1B preferentially binds
Yueren Yan, Ning Wang, Bowen Xing, Min Yang, Jun Shang, Yufang Bao, Lixing Xiao, Ningxia Zhang, Yunpeng Ren, Chunnan Liu, Yuting Chen, Han Han, Yunjian Pan, Lei Lv, Wei‐Xing Zong, Hongbin Ji, Changyou Zhan, Zefeng Wang, Haiquan Chen, Yongbo Wang   +19 more
wiley   +1 more source

Activation of Background Membrane Conductance by the Tyrosine Kinase Inhibitor Tyrphostin A23 and Its Inactive Analog Tyrphostin A1 in Guinea Pig Ventricular Myocytes

, 2001
Toshitsugu Ogura, Sunao Imanishi, Toshishige Shibamoto   +2 more
openalex   +1 more source

The incidence of vascular adverse events and usefulness of novel risk assessment tool in Japanese patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors. [PDF]

Cardiooncology
Watanabe N, Takaku T, Iriyama N, Iwanaga E, Kimura Y, Ishikawa M, Nakayama H, Sato E, Tabayashi T, Mitsumori T, Nakazato T, Tokuhira M, Fujita H, Ando M, Miura K, Kawaguchi T.   +15 more
europepmc   +1 more source